CRC cells develop drug resistance by different mechanisms; in patients bearing the G12V mutation in the KRAS gene, it has been shown that high levels of HIF-1α are associated with resistance to Cetuximab. The gene discussed is KRAS; the disease is colorectal carcinoma.